Eileen M. Barry

Eileen M. Barry serves as Professor in the Department of Medicine at the University of Maryland School of Medicine, with secondary appointments in Medical and Research Technology and Microbiology and Immunology. She directs education for the Center of Vaccine Development & Global Health, leading research on vaccines against enteric pathogens and biodefense threats.

Her academic background includes:

• B.A. in Biology from University of Delaware (1985)
• Ph.D. in Microbiology and Immunology from Virginia Commonwealth University Medical College of Virginia (1991)
• Postdoctoral Fellowship at University of Maryland School of Medicine Center for Vaccine Development (1992-1994)
• Postdoctoral Fellowship at University of Maryland School of Medicine Center for Vaccine Development (1994-1996)

Dr. Barry's research focuses on oral live attenuated vaccines targeting Shigella, enterotoxigenic E. coli (ETEC), and Francisella tularensis. Her work spans pathogen engineering, host-pathogen interactions, and clinical translation, with emphasis on pediatric and military applications. Key methodologies include human enteroid models, BSL3/ABSL3 pathogenesis studies, and immunogenicity assessment. Recent publications reveal a strategic shift toward multivalent platforms and advanced organoid systems for predicting human immune responses.

Her scientific recognition includes:

• University System of Maryland PROMISE Alliance Outstanding Faculty Mentor (2015)
• Faculty Teacher of the Year Award (2011)
• Teaching Commendation in Host Defenses (2009/2012)

As a dedicated mentor, Dr. Barry has served on Graduate Student Admissions Committees since 2007 and received special recognition for advancing underrepresented STEM students. Her substantial NIH funding portfolio includes:

• P01AI125181: Pathogenesis of E. Coli and Shigella in Human Enteroid Models (2016-2021)
• R01AI125841: Serological Assays for Shigella Vaccine Efficacy (2016-2021)
• R01AI123129: Tularemia Vaccine Protection Correlates (2016-2021)

Her laboratory operates BSL2/3 and ABSL2/3 facilities, integrating genetic engineering, organoid models, and genomics to dissect enteric pathogenesis and accelerate vaccine development for global health impact.